NLK is a novel therapeutic target for PTEN deficient tumour cells.

NLK is a novel therapeutic target for PTEN deficient tumour cells.

Item
http://www.wikidata.org/entity/Q41665683
Therapeutic targeting of cancers with loss of PTEN function.Drugging the addict: non-oncogene addiction as a target for cancer therapyControl of stem cell self-renewal and differentiation by the heterochronic genes and the cellular asymmetry machinery in Caenorhabditis elegans.Upregulation of nemo-like kinase is an independent prognostic factor in colorectal cancer.The impact of germline mutations on targeted therapy.Targeting tumor suppressor genes for cancer therapy.The kinome 'at large' in cancer.Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer.Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study.Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.Targeting the cell cycle in breast cancer: towards the next phase
P2860

NLK is a novel therapeutic target for PTEN deficient tumour cells.

Item
http://www.wikidata.org/entity/Q41665683
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
NLK is a novel therapeutic target for PTEN deficient tumour cells.
@en
type
label
NLK is a novel therapeutic target for PTEN deficient tumour cells.
@en
prefLabel
NLK is a novel therapeutic target for PTEN deficient tumour cells.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
NLK is a novel therapeutic target for PTEN deficient tumour cells.
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0047249
P407
P433
P478
P50
P577
P5875
P698
P932